Biotech News
Related news
ERASErasca2026-07-13 20:01 EST
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
ERASErasca2026-08-11 20:01 EST
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
RVMDRevolution Medicines2026-06-22 12:00 EST
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
GERNGeron2026-07-13 12:00 EST
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-08-11 20:01 EST
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERASErasca2026-08-10 20:01 EST
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ERASErasca2026-08-10 12:00 EST
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
ERASErasca2026-07-15 20:01 EST
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ERASErasca2026-07-14 03:10 EST
Erasca Announces Pricing of Upsized Public Offering of Common Stock
Stock data
- Close
- 18.28 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States